Phase II Study of ME-401 with Rituximab-Bendamustine for High-Risk and Rituximab with ME-401 Randomization for Low-Risk Follicular Lymphoma Treatment

The primary objective of this phase II study is to evaluate the efficacy of **ME-401** in combination with rituximab-bendamustine for high-risk patients, and rituximab with a 1:1 randomization to ME-401 for low-risk patients, as a primary treatment for **Follicular Lymphoma**. This study aims to determine the therapeutic potential of ME-401 in improving treatment outcomes for patients with varying risk levels of this type of lymphoma, which is a common form of non-Hodgkin lymphoma characterized by slow progression but challenging treatment responses. The clinical relevance of this study lies in its potential to enhance first-line treatment strategies, thereby improving patient prognosis and quality of life.

The clinical trial involves participants diagnosed with **Follicular Lymphoma**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. The trial population was selected to include a vulnerable population, although specific details regarding the total number of participants have not been provided by the sponsor. The general health status of participants is not specified, nor are any lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been disclosed, and the main objective of the trial remains unspecified.

The clinical trial is designed to evaluate the efficacy and safety of **ME-401** combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk **Follicular Lymphoma** as a primary treatment. This is a phase II study, employing a randomized, double-blind, controlled trial design. The trial is expected to commence recruitment on September 1, 2022, and is estimated to conclude by December 31, 2027. Participants will be involved in the study for the duration of the trial, with specific timelines for each phase of participation.

The sequence of study visits begins with an inclusion (screening) visit, where eligibility criteria are assessed to ensure participants meet the necessary conditions for trial entry. Following successful screening, participants will undergo randomization and commence treatment as per their assigned group. Regular follow-up visits will be scheduled to monitor the participants' response to treatment, assess safety, and collect data on primary and secondary endpoints. These visits are crucial for evaluating the trial's progress and ensuring participant safety. The end-of-study visit will mark the conclusion of a participant's involvement, where final assessments will be conducted to gather comprehensive data on the treatment's long-term effects.

Participant involvement is expected to last throughout the trial duration, with specific conditions outlined for early termination. These conditions may include adverse events, withdrawal of consent, or any other factors that compromise participant safety or data integrity. The trial's methodology and design are structured to ensure rigorous data collection and analysis, contributing to the understanding of ME-401's role in treating **Follicular Lymphoma**. The study's findings will be pivotal in determining the potential benefits and risks associated with the treatment regimen under investigation.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy within the context of a Phase 4 study. The trial is scheduled to commence recruitment on September 1, 2022, with an estimated completion date of December 31, 2027. Efficacy assessments will be conducted at predetermined intervals throughout the trial duration. The specific parameters or endpoints used to evaluate efficacy, as well as the methods and schedule for measuring, collecting, and analyzing these parameters, are not detailed in the provided data. The trial will adhere to standard protocols for Phase 4 studies, ensuring that all efficacy assessments are conducted using scientifically validated methods and tools appropriate for the condition under investigation. The trial's design will facilitate the collection of robust data to evaluate the efficacy of the intervention under real-world conditions.